<DOC>
	<DOC>NCT01292837</DOC>
	<brief_summary>To evaluate the efficacy and safety of Levetiracetam dry syrup at doses up to 60 mg/kg/day or 3000 mg/day used as adjunctive therapy in Japanese pediatric patients aged â‰¥4 to &lt;16 years with uncontrolled Generalized Tonic-Clonic (GTC) seizures despite treatment with 1 or 2 Anti-Epileptic Drugs (AEDs).</brief_summary>
	<brief_title>A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>An epileptic patient with generalized tonicclonic seizures that are classifiable according to the International League Against Epilepsy classification of epileptic seizures (Epilepsia, 1981) A patient on a stable dose of 1 or 2 antiepileptic drugs for the last 4 weeks (potassium bromide and sodium bromide for the last 12 weeks) prior to the Combined Baseline Period and during the Combined Baseline Period Presence of any sign (clinical or imaging procedures) suggesting a progressive brain lesion/disease, in particular, progressive disorder with epileptic seizures Diagnosis of LennoxGastaut Syndrome Confirmed focal epilepsy based on clinical signs (seizure types), with consistent electroencephalogram and magnetic resonance imaging features A history of convulsive or nonconvulsive status epilepticus while taking concomitant antiepileptic drugs for the last 3 months prior to Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Generalized tonic-clonic seizures</keyword>
</DOC>